Original Articles:

• Durvalumab, Tremelimumab, and Platinum Chemotherapy in EGFR Mutation–Positive NSCLC: An Open-Label Phase 2 Trial (ILLUMINATE)
• Afatinib and Necitumumab in EGFR-Mutant NSCLC with Acquired Resistance to Tyrosine Kinase Inhibitors
• Next-Generation Sequencing Analysis on Image-Guided Biopsy Samples in Early-Stage Lung Cancer: Feasibility Study and Comparison With Surgical Samples
• Impact of Prophylactic Use of PEG-rhG-CSF on First-Line Immunochemotherapy in Advanced NSCLC: A Cohort Study

Case Report

• EGFR-Mutated Lung Adenocarcinoma With Li–Fraumeni Syndrome: The Imperative for Germline Testing in Patients With a Family History, a Case Report

JTO Clinical and Research Reports is the official open access journal of the International Association for the Study of Lung Cancer. It aims to complement the Journal of Thoracic Oncology by offering authors a gold open access publication option and publishing the following article types in particular:

• Phase I trials
• Well performed single-arm phase II trials
• Subset analyses of published trials
• Impactful retrospective Studies
• Database analysis
• Large institutional series
• High-quality case reports
• Region-specific clinical trials
• Subspecialty thoracic oncology studies
• Selected high-quality meeting reports

As an open access journal with no subscription charges, JTO CRR requires authors to pay a fee to cover the costs associated with publication. This ensures your article will be immediately and permanently free to access by everyone.